Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâ€™s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Employees

Sector

Biotechnology & Medical Research

More about the company

01/25/01	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
01/25/01	Oncternal Therapeutics, Inc. Announces Management Changes	CI
05/24/05	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index	CI
02/24/02	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index	CI
25/24/25	Top Premarket Decliners	MT
07/24/07	Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
23/24/23	Oncternal Therapeutics Continues to Explore Strategic Alternatives	CI
22/24/22	Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
13/24/13	Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534	CI
13/24/13	Oncternal Therapeutics, Inc. Announces Workforce Reduction	CI
13/24/13	Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024	CI
13/24/13	Sector Update: Health Care Stocks Rise in Thursday Trading	MT
12/24/12	Oncternal Therapeutics Announces Exploration of Strategic Alternatives	CI

12/24/12	Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	MT
15/24/15	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT
04/23/04	Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	MT
18/23/18	HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	MT
04/23/04	Maxim Downgrades Oncternal Therapeutics to Hold From Buy	MT

08/25/08	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC	AQ
25/24/25	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
22/24/22	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
12/24/12	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives	AQ
09/24/09	Oncternal Therapeutics: Q2 Earnings Snapshot	AQ

3 years	0.53	13.14
5 years	0.53	89.8
10 years	0.53	211.2

Manager	Title	Age	Since
Richard Vincent DFI	Director of Finance/CFO	63	01/04/2017
Yisrael Katz CTO	Chief Tech/Sci/R&D Officer	-	01/07/2023
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	53	-

Oncternal Therapeutics, Inc. Share Price

Stocks

ONCT

US68236P2065

Biotechnology & Medical Research

Latest news: Oncternal Therapeutics, Inc.

Analysts' recommendations: Oncternal Therapeutics, Inc.

Press Releases: Oncternal Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Oncternal Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Director	Title	Age	Since
Dan Kisner BRD	Director/Board Member	79	07/06/2019
William LaRue BRD	Director/Board Member	75	01/12/2017
Xin Nakanishi BRD	Director/Board Member	64	01/11/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/06/24	Michael Carter	Free	Director	2,200	0.0743%
20/06/24	Charles Theuer	Free	Director	2,200	0.0743%
20/06/24	Dan Kisner	Free	Director	2,200	0.0743%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCTERNAL THERAPEUTICS, INC.	-24.11%	-.--%	-	-	15.59L
WUXI APPTEC CO., LTD.	-4.10%	-8.54%	+40.05%	+66.99%	6.33TCr
ARGENX SE	+0.03%	+7.75%	+11.27%	+73.87%	5.49TCr
LONZA GROUP AG	+0.60%	+4.64%	+10.10%	+92.92%	5.33TCr
IQVIA HOLDINGS INC.	+0.61%	+2.69%	+27.75%	+50.97%	4.58TCr
BEONE MEDICINES AG	-1.08%	+2.19%	+21.92%	+131.38%	4.35TCr
REVOLUTION MEDICINES, INC.	-3.39%	-0.83%	+254.27%	+571.04%	4.02TCr
CELLTRION, INC.	-1.67%	+6.70%	+14.42%	+56.67%	3.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.76%	2.37TCr
GENMAB A/S	-0.34%	+5.48%	+36.17%	+27.30%	2.38TCr
Average	-3.22%	+0.46%	+49.44%	+118.93%	4.24TCr
Weighted average by Cap.	-1.09%	+0.59%	+47.59%	+122.53%